1-6 of 6
Mark Shapiro, MD PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Patient-Reported Outcomes from a Global Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard of Care Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia

Hagop M. Kantarjian, MD, Yun Su, MD MPH, Elias J. Jabbour, MD, Helen Bhattacharyya, PhD, Eric Yan, PhD, Mark Shapiro, MD PhD, Joseph C. Cappelleri, PhD MPH, MS, David I. Marks, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1599.
https://doi.org/10.1182/blood.V128.22.1599.1599
Published: 2016
Journal Articles

Matching-Adjusted Indirect Treatment Comparison of Bosutinib, Dasatinib, Nilotinib and Ponatinib on Survival for Second Line Chronic Phase Chronic Myeloid Leukemia Patients

Bogdan Muresan, MS, Carla Mamolo, PhD, Joseph C. Cappelleri, PhD MPH, MS, Mark Shapiro, MD PhD, Rocco J. Crescenzo, DO, FACOI, Yun Su, MD MPH, Bart Heeg, PhD
Journal: Blood
Blood (2016) 128 (22): 3095.
https://doi.org/10.1182/blood.V128.22.3095.3095
Published: 2016
Journal Articles

Efficacy and Safety Following Bosutinib Dose Reduction in Patients with Philadelphia Chromosome‒Positive Chronic Myeloid Leukemia

Vamsi Kota, MD, Tim H. Brümmendorf, MD, Carlo Gambacorti-Passerini, MD, Jorge E. Cortes, MD, Jeffrey H. Lipton, MD PhD, Hagop M. Kantarjian, MD, Dong-Wook Kim, MD PhD, Fiona An, MD, Eric Leip, PhD, Rocco J. Crescenzo, DO, FACOI, Mabel Woloj, PhD, Mark Shapiro, MD PhD, H. Jean Khoury, MD FACP
Journal: Blood
Blood (2016) 128 (22): 1921.
https://doi.org/10.1182/blood.V128.22.1921.1921
Published: 2016
Journal Articles

Real World Analysis Of Duration Of TKI Treatment Among Patients With Chronic Myeloid Leukemia

Henry J Henk, PhD, Mabel Woloj, PhD, Mark Shapiro, MD, PhD, Jennifer Whiteley, EdD
Journal: Blood
Blood (2013) 122 (21): 5175.
https://doi.org/10.1182/blood.V122.21.5175.5175
Published: 2013
Journal Articles

Safety and Clinical Activity of the Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) in Combination with Rituximab in Follicular Lymphoma or Diffuse Large B-Cell Lymphoma: Preliminary Report of a Phase 1/2 Study

Luis Fayad, Hemant Patel, PhD, Gregor Verhoef, Mitchell R. Smith, Peter W.M. Johnson, MD, FRCP, Myron S. Czuczman, MD, Bertrand Coiffier, Georg Hess, Eva Gine, Anjali Advani, MD, Fritz Offner, MD, Erik R. Vandendries, MD, PhD, Mark Shapiro, MD, PhD, FACP, Nam H. Dang, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 266.
https://doi.org/10.1182/blood.V112.11.266.266
Published: 2008
Journal Articles

Clinical Activity of the Immunoconjugate CMC-544 in B-Cell Malignancies: Preliminary Report of the Expanded Maximum Tolerated Dose (MTD) Cohort of a Phase 1 Study.

Luis Fayad, MD, Hemant Patel, PhD, Gregor Verhoef, MD, PhD, Myron Czuczman, MD, James Foran, MD, Eva Gine, MD, Ama Rohatiner, MD, Mitchell R. Smith, MD, Mark Shapiro, MD, PhD, Anjali Advani, MD
Journal: Blood
Blood (2006) 108 (11): 2711.
https://doi.org/10.1182/blood.V108.11.2711.2711
Published: 2006